Effect of new manganese contrast agent on tissue intensities in human volunteers: Comparison of 0.23, 0.6 and 1.5T MRI, a part of a phase I trail

Magnetic Resonance Materials in Physics, Biology and Medicine

Volumn 17, Issue 1, 2004, Pages 28-35

  Chabanova, E ^a   Thomsen, H S ^a   Logager V ^a   Moller, J M ^a   Brage, K ^a   Fogh, K ^a   Bovin, J ^a   Elmig, J ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Contrast agent; Liver; Manganese; MRI; Oral intake

Indexed keywords

ALANINE; ALANINE PLUS COLECALCIFEROL PLUS MANGANESE CHLORIDE; CMC 001; COLECALCIFEROL DERIVATIVE; MANGANESE CHLORIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; IMAGE INTENSIFIER; LIVER; MAGNETIC FIELD; MALE; MUSCLE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 6344291761     PISSN: 09685243     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10334-004-0042-z     Document Type: Article

References (16)

1. Weinmann H-J, Ebert W, Misselwitz B, Schmitt-Willich H (2003) Tissue-specific MR contrast agents. EJR 46:33-44
2. Helmberger T, Semelka RC (2001) New contrast agents for imaging the liver. Magn Res Imaging Clin North Am 9:745-766
3. Oudkerk M, Torres CG, Song B et al. (2002) Characterization of liver lesions with mangafodipir trisodium-enhanced MR imaging: multicenter study comparing MR and dual-phase spiral CT. Radiology 223:517-524
4. Gallez B, Bacic G, Swartz HM (1996) Evidence for the dissociation of the hepatobiliary MRI contrast agent Mn-DPDP. Magn Res Med 35:14-19
5. Brurok H, Schojtt J, Berg K, Karlsson JO, Jynge P (1995) Effects of mangenese dipyridoxyl diphosphate, dipyridoxyl diphosphate and manganese chloride on cardiac function. An experimental study in the Langendorff perfused rat heart. Invest Radiol 30:159-167
6. Ahlstrom H, Gehl HB (1997) Overview of MnDPDP as a pancreas-specific contrast agent for MR imaging. Acta Radiol 38:660-664
7. Thomsen HS, Svendsen O, Klastrup S (2004) Increased manganese concentration in the liver after oral intake. Acad Radiol 11:38-44
8. Thomsen HS, Loegager V, Noergaard H, Chabanova E, Moller JM, Sonne J (2004) Oral manganese for liver imaging at three different field strengths. Acad Radiol 11:630-636
9. Brady TJ, Reimer P (2000) Contrast agents in whole body magnetic resonance: an overview. In: Young IR (ed) Methods in biomedical magnetic resonance imaging and spectroscopy. Wiley, London, pp 693-698
10. Takagi Y, Okada A, Sando K et al. (2002) Evaluation of indexes of in vivo manganese status and the optimal intravenous dose for adult patients undergoing home parenteral nutrition. Am J Clin Nutr 75:112-118
11. Dietz MC, Ihrig A, Bader M, Triebig G (2003) Arbeitsmedizische Feldstudie zur chronischen Neurotoxizität von Mangandioxid. Arbeitsmed Sozialmed Umweltmed 38:57-66
12. Matsuda A, Kimura M, Takeda T et al. (1994) Changes in manganese content of mononuclear blood cells in patients receiving total parental nutrition. Clin Chem 40:829-832
13. Bottomley PA, Foster TH, Argersinger RE, Pfeifer LM (1984) A review of normal tissue hydrogen NMR relaxation times and relaxation mechanisms from 1-100 MHz: dependence on tissue type, NMR frequency, temperature, species, excision, and age. Med Phys 11:425-448
14. Koenig SH, Brown RD, Adams D et al. (1984) Magnetic field dependence of 1/T1 in tissue. Invest Radiol 19:76
15. Hoult DI (2000) Sensitivity of whole body MRI experiments. In: Young IR (ed) Methods in biomedical magnetic resonance imaging and spectroscopy. Wiley, London, pp 65-74
16. McNamara MT (1987) Paramagnetic contrast material. In: Higgings CB, Hriak H (eds) Magnetic resonance imaging of the body. Raven Press, New York, pp 547-558